1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H1, 2014

Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Hepatocellular Carcinoma (HCC) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Hepatocellular Carcinoma (HCC). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Hepatocellular Carcinoma (HCC). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 9
Metastatic Hepatocellular Carcinoma (HCC) 9
Report Guidance 9
Clinical Trials by Region 10
Clinical Trials and Average Enrollment by Country 11
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 13
Top Five Countries Contributing to Clinical Trials in Europe 14
Top Countries Contributing to Clinical Trials in North America 15
Top Countries Contributing to Clinical Trials in Middle East and Africa 16
Clinical Trials by G7 Countries: Proportion of Metastatic Hepatocellular Carcinoma (HCC) to Oncology Clinical Trials 17
Clinical Trials by Phase in G7 Countries 18
Clinical Trials in G7 Countries by Trial Status 19
Clinical Trials by E7 Countries: Proportion of Metastatic Hepatocellular Carcinoma (HCC) to Oncology Clinical Trials 20
Clinical Trials by Phase in E7 Countries 21
Clinical Trials in E7 Countries by Trial Status 22
Clinical Trials by Phase 23
In Progress Trials by Phase 24
Clinical Trials by Trial Status 25
Clinical Trials by End Point Status 26
Unaccomplished Trials of Metastatic Hepatocellular Carcinoma (HCC) 27
Subjects Recruited Over a Period of Time 29
Clinical Trials by Sponsor Type 30
Prominent Sponsors 31
Top Companies Participating in Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials 32
Prominent Drugs 34
Latest Clinical Trials News on Metastatic Hepatocellular Carcinoma (HCC) 35
Dec 13, 2013: Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I Clinical Trial for Liver Cancer 35
Aug 22, 2013: Cellular Biomedicine Announces Completion of Patient Enrollment for Phase I Clinical Trial for Liver Cancer 35
May 22, 2013: Cellular Biomedicine Announces Enrollment Milestone For Phase I Clinical Trial For Liver Cancer 36
May 21, 2013: 4SC's Partner Yakult Honsha Starts Clinical Phase I/II Study With Cancer Compound Resminostat In Liver Cancer In Japan 36
May 13, 2013: Marina Biotech's Licensee Mirna Therapeutics Initiates Phase I Clinical Trial Of Anticancer Drug MRX34 37
Clinical Trial Profiles 38
Clinical Trial Overview of Top Companies 38
Pfizer Inc. 38
Clinical Trial Overview of Pfizer Inc. 38
F. Hoffmann-La Roche Ltd. 39
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 39
AstraZeneca PLC 40
Clinical Trial Overview of AstraZeneca PLC 40
Bayer AG 41
Clinical Trial Overview of Bayer AG 41
Novartis AG 42
Clinical Trial Overview of Novartis AG 42
MolMed S.p.A. 43
Clinical Trial Overview of MolMed S.p.A. 43
Immunomedics, Inc. 44
Clinical Trial Overview of Immunomedics, Inc. 44
Eli Lilly and Company 45
Clinical Trial Overview of Eli Lilly and Company 45
Affitech A/S 46
Clinical Trial Overview of Affitech A/S 46
Adherex Technologies Inc. 47
Clinical Trial Overview of Adherex Technologies Inc. 47
Clinical Trial Overview of Top Institutes / Government 48
National Cancer Institute 48
Clinical Trial Overview of National Cancer Institute 48
UNC Lineberger Comprehensive Cancer Center 49
Clinical Trial Overview of UNC Lineberger Comprehensive Cancer Center 49
North Central Cancer Treatment Group 50
Clinical Trial Overview of North Central Cancer Treatment Group 50
Far Eastern Memorial Hospital 51
Clinical Trial Overview of Far Eastern Memorial Hospital 51
Thomas Jefferson University 52
Clinical Trial Overview of Thomas Jefferson University 52
Leiden University Medical Center 53
Clinical Trial Overview of Leiden University Medical Center 53
The University of Hong Kong 54
Clinical Trial Overview of The University of Hong Kong 54
University of Florida 55
Clinical Trial Overview of University of Florida 55
Five Key Clinical Profiles 56
Appendix 99
Abbreviations 99
Definitions 99
Research Methodology 100
Secondary Research 100
About GlobalData 101
Contact Us 101
Disclaimer 101
Source 102

List of Tables
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, Global, Clinical Trials by Region, 2014* 10
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 11
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 12
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 13
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 14
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, North America, Top Countries, 2014* 15
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 16
Proportion of Metastatic Hepatocellular Carcinoma (HCC) to Oncology Clinical Trials, G7 Countries (%), 2014* 17
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 18
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 19
Proportion of Metastatic Hepatocellular Carcinoma (HCC) to Oncology Clinical Trials, E7 Countries (%), 2014* 20
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 21
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 22
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, Global, Clinical Trials by Phase, 2014* 23
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 24
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 25
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 26
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, Global, Suspended Clinical Trials, 2014* 27
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, Global, Terminated Clinical Trials, 2014* 28
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 29
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 30
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 31
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 33
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 34
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 38
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 39
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 40
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014* 41
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 42
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials Market, Global, Clinical Trials by MolMed S.p.A., 2014* 43
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials Market, Global, Clinical Trials by Immunomedics, Inc., 2014* 44
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 45
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials Market, Global, Clinical Trials by Affitech A/S, 2014* 46
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials Market, Global, Clinical Trials by Adherex Technologies Inc., 2014* 47
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 48
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials Market, Global, Clinical Trials by UNC Lineberger Comprehensive Cancer Center, 2014* 49
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials Market, Global, Clinical Trials by North Central Cancer Treatment Group, 2014* 50
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials Market, Global, Clinical Trials by Far Eastern Memorial Hospital, 2014* 51
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials Market, Global, Clinical Trials by Thomas Jefferson University, 2014* 52
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials Market, Global, Clinical Trials by Leiden University Medical Center, 2014* 53
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Hong Kong, 2014* 54
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Florida, 2014* 55

List of Figures
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, Global, Clinical Trials by Region (%), 2014* 10
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 11
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 12
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 13
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 14
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 15
Proportion of Metastatic Hepatocellular Carcinoma (HCC) to Oncology Clinical Trials, G7 Countries (%), 2014* 17
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 18
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 19
Proportion of Metastatic Hepatocellular Carcinoma (HCC) to Oncology Clinical Trials, E7 Countries (%), 2014* 20
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 21
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 22
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 23
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 24
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 25
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 26
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 29
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 30
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 31
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 32
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 34
GlobalData Methodology 100

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • $ 10995
  • Industry report
  • October 2016
  • by Global Data

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Summary Hepatitis C is a blood-borne viral infection ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in the Netherlands

  • January 2017
    5 pages
  • Therapy  

  • Netherlands  

View report >

Antidepressant Market and Bipolar Disorder Statistics in the UK

  • January 2017
    9 pages
  • Antidepressant  

    Bipolar Disorde...  

    Depression  

  • United Kingdom  

View report >

Therapy Market in Uganda

  • January 2017
    22 pages
  • Therapy  

  • Uganda  

    Africa  

View report >

Therapy Market

28 hours ago

Diabetes Statistics

28 hours ago

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.